The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma

doi:10.1111/1751-2980.12866

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24403

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24403

Title:	The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma
Authors:	Lee, SW;Lee, TY;Peng, YC;Yang, SS;Yeh, HZ;Chang, CS
Keywords:	hepatocellular carcinoma;sorafenib;transarterial chemoembolization
Date:	2020
Issue Date:	2022-08-09T08:01:43Z (UTC)
Publisher:	WILEY
ISSN:	1751-2972
Abstract:	Objective Systemic therapy, such as sorafenib, has been used clinically to treat patients with advanced stage or Barcelona Clinic Liver Cancer staging system (BCLC) stage C hepatocellular carcinoma (HCC). The aim of the study was to evaluate the therapeutic benefit of combined sorafenib and transarterial chemoembolization (TACE) in this group of patients. Methods Data on patients with HCC at BCLC stage C from August 2012 to September 2017 were collected. Patients who were given sorafenib alone were classified as the monotherapy group and those taking sorafenib and TACE were classed as the combined therapy group. Results A total of 118 patients were enrolled. There were 65 and 53 patients in the monotherapy and the combined therapy group, respectively. The groups' general characteristics were similar. Compared with the monotherapy group the combined therapy group experienced prolonged time-to-progression (TTP) (mean 6.42 mo vs 3.63 mo, P = 0.003) and overall survival (OS) (mean 11.21 mo vs 5.98 mo, P = 0.001). A subgroup analysis found that patients with macroscopic vascular invasion (MVI) also had prolonged TTP and OS in the combined therapy group than the monotherapy group (mean TTP, 7.93 mo vs 3.43 mo, P = 0.007; mean OS, 13.41 mo vs 5.50 mo, P = 0.001), however, these significant differences did not exist for those with extrahepatic spread (EHS). Conclusion Combined sorafenib and TACE therapy has significant better outcomes than sorafenib alone in patients with stage C HCC, particularly those with MVI.
URI:	http://dx.doi.org/10.1111/1751-2980.12866 https://www.webofscience.com/wos/woscc/full-record/WOS:000537512000001 https://ir.csmu.edu.tw:8080/handle/310902500/24403
Relation:	JOURNAL OF DIGESTIVE DISEASES ,2020 ,v21 ,issue 5 ,p287-292
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	198	View/Open

Loading...